These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37540701)

  • 1. Testing the mutant selection window hypothesis with meropenem: In vitro model study with OXA-48-producing Klebsiella pneumoniae.
    Alieva KN; Golikova MV; Dovzhenko SA; Kobrin MB; Strukova EN; Ageevets VA; Avdeeva AA; Sulian OS; Sidorenko SV; Zinner SH
    PLoS One; 2023; 18(8):e0288660. PubMed ID: 37540701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of a New Variant OXA-204 and OXA-48 Carbapenemases Plasmids Encoded in Klebsiella pneumoniae Clinical Isolates in Tunisia.
    Ouertani R; Ben Jomàa-Jemili M; Gharsa H; Limelette A; Guillard T; Brasme L; de Champs C; Chouchani C
    Microb Drug Resist; 2018 Mar; 24(2):142-149. PubMed ID: 28737463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
    Poirel L; Kieffer N; Nordmann P
    J Antimicrob Chemother; 2016 Jan; 71(1):156-61. PubMed ID: 26416781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates.
    Abdel-Halim MS; Askoura M; Mansour B; Yahya G; El-Ganiny AM
    J Antibiot (Tokyo); 2022 Dec; 75(12):679-690. PubMed ID: 36167781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic, molecular, and in silico characterization of coumarin as carbapenemase inhibitor to fight carbapenem-resistant Klebsiella pneumoniae.
    Abdel-Halim MS; El-Ganiny AM; Mansour B; Yahya G; Latif HKAE; Askoura M
    BMC Microbiol; 2024 Feb; 24(1):67. PubMed ID: 38413891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of in vitro efficacy of quercetin-meropenem combination in carbapenemase-producing Klebsiella pneumoniae isolates.
    Aydemir Ö; Ormanoğlu G; Ayhancı T; Zengin M; Köroğlu M
    J Infect Dev Ctries; 2023 Sep; 17(9):1325-1329. PubMed ID: 37824360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
    Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence study on carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolates in Czech hospitals--results from Czech Part of European Survey on Carbapenemase--Producing Enterobacteriaceae (EuSCAPE).
    Hrabák J; Študentová V; Jakubů V; Adámková V; Dvořáková L; Balejova M; Bergerová T; Chmelařová E; Ježek P; Kabelíková P; Kolář M; Paterová P; Tejkalová R; Papagiannitsis C; Žemličková H
    Epidemiol Mikrobiol Imunol; 2015 Jun; 64(2):87-91. PubMed ID: 26099612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
    Abbas HA; Kadry AA; Shaker GH; Goda RM
    Microb Pathog; 2019 Jul; 132():266-274. PubMed ID: 31096002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Resistance Mechanisms on the Inoculum Effect of Carbapenem in Klebsiella pneumoniae Isolates with Borderline Carbapenem Resistance.
    Adler A; Ben-Dalak M; Chmelnitsky I; Carmeli Y
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5014-7. PubMed ID: 25987630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae.
    Cremanns M; Lange F; Gatermann SG; Pfennigwerth N
    J Antimicrob Chemother; 2022 May; 77(6):1578-1585. PubMed ID: 35265984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.